{
  "meta": {
    "title": "Chronic_Kidney_Disease",
    "url": "https://brainandscalpel.vercel.app/chronic-kidney-disease-847ae134.html",
    "scrapedAt": "2025-11-30T08:49:01.102Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">G3aA3</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">G3aA2</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">G3bA3</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">G3bA2</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What will be the stage of chronic kidney disease of a patient with eGFR of 40 ml/min and persistent proteinuria of >300 mg/g?</span></p>",
      "unique_key": "DT1295628",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295628,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Chronic Kidney Disease (CKD) Staging:</strong>\r\n<ul>\r\n<li><strong>Stage Classification:</strong> CKD is classified based on <strong>glomerular filtration rate (GFR)</strong> and the degree of <strong>proteinuria</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>eGFR of 40 ml/min:</strong>\r\n<ul>\r\n<li>This corresponds to <strong>Stage G3b</strong> (GFR 30-44 ml/min).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Persistent Proteinuria of &gt;300 mg/g:</strong>\r\n<ul>\r\n<li>This indicates <strong>A3</strong> (high proteinuria &gt;300 mg/g).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Combined Staging:</strong>\r\n<ul>\r\n<li>Therefore, the stage is <strong>G3bA3</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025011812a8de66-3170-4588-8a34-a6d218f25db8.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong> G3aA3:</strong> Incorrect; G3a corresponds to eGFR of 45-59 ml/min.</li>\r\n<li><strong> G3aA2:</strong> Incorrect; also corresponds to eGFR of 45-59 ml/min.</li>\r\n<li><strong> G3bA2:</strong> Incorrect; while G3b is correct, A2 indicates lower proteinuria (&lt;300 mg/g).</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The patient's CKD stage is <strong>G3bA3</strong> due to <strong>eGFR of 40 ml/min</strong> and <strong>high proteinuria</strong>.</li>\r\n<li>Understanding CKD staging is crucial for appropriate management and monitoring of renal function.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Short for gestational age</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Alcohol intake</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Preeclampsia</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Smoking</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a risk factor for Chronic Kidney disease?</span></p>",
      "unique_key": "DT1295629",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295629,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Alcohol Intake:</strong> While excessive alcohol can harm overall health, it is not directly classified as a significant risk factor for CKD.</li>\r\n<li><strong>Short for Gestational Age:</strong> Linked to developmental issues, increasing the likelihood of kidney disease later in life due to inadequate nephron development.</li>\r\n<li><strong>Preeclampsia:</strong> Associated with an increased risk of CKD due to potential kidney damage during pregnancy.</li>\r\n<li><strong>Smoking:</strong> Recognized as a contributing factor to renal impairment by affecting blood flow and promoting chronic inflammation.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A (Short for Gestational Age):</strong> This condition predisposes individuals to kidney disease later due to impaired nephron development, thus it is a risk factor.</li>\r\n<li><strong>C (Preeclampsia):</strong> This condition leads to renal complications during pregnancy and heightens the risk of future kidney disease, making it a risk factor.</li>\r\n<li><strong>D (Smoking):</strong> Smoking is known to exacerbate kidney disease and contribute to its progression through vascular damage and reduced renal blood flow.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Identifying Risk Factors:</strong> Understanding the correct risk factors for CKD is crucial for early diagnosis and intervention.</li>\r\n<li><strong>Lifestyle Modifications:</strong> Reducing risk through smoking cessation and managing conditions like hypertension can help prevent CKD.</li>\r\n<li><strong>Monitoring and Assessment:</strong> Regular assessment of renal function and risk factors, such as albuminuria, can guide treatment and management strategies effectively.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-Anion gap metabolic acidosis</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Anion gap metabolic acidosis</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypochloremic Metabolic acidosis</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following forms of metabolic acidosis is seen in early stages of Chronic Kidney disease?</span></p>",
      "unique_key": "DT1295631",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295631,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Metabolic acidosis</strong> is common in Chronic Kidney Disease (CKD), typically presenting as <strong>hyperkalemic and hyperchloremic</strong> metabolic acidosis, even in earlier stages.</li>\r\n<li><strong>Non-anion gap metabolic acidosis</strong> appears in early CKD and can later develop into <strong>anion-gap metabolic acidosis</strong> as the disease progresses.</li>\r\n<li>Most patients experience <strong>mild metabolic acidosis</strong> (pH rarely &lt; 7.32), which is often correctable with <strong>oral sodium bicarbonate</strong></li>\r\n<li>Even mild acidosis can enhance <strong>protein catabolism</strong> and expedite CKD progression, emphasizing the need for early detection and management.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>Option B (Anion gap metabolic acidosis)</strong> is more typical of advanced CKD due to accumulation of acids and toxins.</li>\r\n<li><strong>Option C (Hypochloremic Metabolic acidosis)</strong> is not commonly associated with CKD; instead, hyperchloremia is more frequent.</li>\r\n<li><strong>Option D (None of the above)</strong> is incorrect, as non-anion gap metabolic acidosis is indeed observed in early CKD.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong><br /> <strong>Non-anion gap metabolic acidosis</strong> is prevalent in <strong>early CKD</strong> and can be managed with oral sodium bicarbonate. Early intervention is critical, as even slight metabolic acidosis may lead to increased protein catabolism and hasten CKD progression.</p>\r\n ",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases tubular calcium Absorption.</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases Tubular Calcium Excretion</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases Tubular Phosphate Absorption.</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases Tubular Phosphate Excretion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the function of Fibroblast Growth Factor 23(FGF23) in calcium and phosphate metabolism?</span></p>",
      "unique_key": "DT1295633",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295633,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>FGF-23</strong> is a phosphatonin that primarily functions to <strong>promote phosphate excretion</strong> from the kidneys.</li>\r\n<li>In Chronic Kidney Disease (CKD), <strong>phosphate retention</strong> occurs due to a declining glomerular filtration rate (GFR), leading to increased FGF-23 levels. However, this increase is ineffective at promoting excretion due to reduced GFR.</li>\r\n<li>Elevated FGF-23 inhibits the formation of <strong>calcitriol (active vitamin D)</strong>, resulting in <strong>hypocalcemia</strong>. This low calcium level stimulates <strong>secondary hyperparathyroidism</strong>.</li>\r\n<li>Metabolic changes in calcium and phosphate begin when GFR falls below <strong>60 ml/min</strong>, highlighting the importance of early intervention.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (Increases tubular calcium absorption)</strong> is incorrect; FGF-23 does not enhance calcium absorption.</li>\r\n<li><strong>Option B (Increases tubular calcium excretion)</strong> is also incorrect; FGF-23 primarily affects phosphate, not calcium excretion.</li>\r\n<li><strong>Option C (Increases tubular phosphate absorption)</strong> is incorrect as FGF-23 actually decreases phosphate reabsorption in the kidneys, promoting excretion instead.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:<br /> </strong><br /> <strong>FGF-23 plays a crucial role in phosphate metabolism by promoting its excretion</strong>, especially in CKD where its accumulation occurs due to <strong>reduced GFR</strong>. Understanding its function is vital, as <strong>low calcitriol levels from increased FGF-23</strong> can lead to <strong>secondary hyperparathyroidism</strong> and complications in mineral metabolism.</p>\r\n ",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Brown Tumour</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteitis fibrosa cystica</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Tumoral Calcinosis</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a manifestation of hyperparathyroidism in CKD?</span></p>",
      "unique_key": "DT1295634",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295634,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Hyperparathyroidism</strong> in CKD stimulates bone turnover and leads to conditions like <strong>osteitis fibrosa cystica</strong> and <strong>brown tumors</strong>, causing significant bone pain and fragility.</li>\r\n<li><strong>PTH</strong> is classified as a <strong>uremic toxin</strong>, with elevated levels linked to various complications, including <strong>muscle weakness</strong> and <strong>fibrosis</strong> of cardiac muscle.</li>\r\n</ul>\r\n<p>Manifestations of <strong>Hypoparathyroid</strong> state in CKD include:</p>\r\n<ul>\r\n<li><strong>Adynamic bone disease</strong> characterized by reduced bone volume and mineralization and may result from excessive suppression of PTH production, chronic inflammation, or both</li>\r\n<li>Complications of adynamic bone disease include an increased incidence of fracture and bone pain and an association with increased vascular and cardiac calcification. calcium will precipitate in the soft tissues into large concretions termed <strong>tumoral calcinosis.</strong></li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A. Brown Tumour:</strong> This is a classic manifestation of severe hyperparathyroidism due to increased osteoclastic activity and bone resorption.</li>\r\n<li><strong>B. Osteitis fibrosa cystica:</strong> This condition arises from prolonged high PTH levels, causing significant bone remodeling and damage.</li>\r\n<li><strong>D. All of the above:</strong> Since A and B are correct manifestations of hyperparathyroidism, this option is incorrect.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hyperparathyroidism</strong> in CKD causes significant bone turnover, leading to <strong>osteitis fibrosa cystica</strong> and <strong>brown tumors</strong>.</li>\r\n<li><strong>Tumoral calcinosis</strong> is linked to <strong>adynamic bone disease</strong>, where low PTH levels result in soft tissue calcium deposition, not elevated PTH levels.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Vasculitis</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardio embolism causing obstruction of cutaneous vessel resulting in skin infarct</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Necrotizing infection</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Calciphylaxis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A diagnosed case of CKD on WARFARIN for atrial Fibrillation presents with painful nodule on abdomen that is followed by progressive Narrowing of the abdominal skin. The Image is shown below. What is the most likely diagnosis?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109e60f02d6-92ea-4c08-8e86-8a594a0bacff.jpg\"></span></p>",
      "unique_key": "DT1295636",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295636,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Calciphylaxis</strong> is a severe condition primarily affecting patients with <strong>advanced CKD</strong>, often presenting with <strong>painful livedo reticularis</strong> and subcutaneous nodules that progress to <strong>ischemic necrosis</strong>.</li>\r\n<li>This condition is <strong>characterized by extensive vascular and soft tissue calcification</strong>, leading to <strong>vascular occlusion</strong>. It is especially concerning in areas like the <strong>abdomen, thighs, and legs</strong>.</li>\r\n<li><strong>Warfarin therapy</strong> is a notable risk factor for calciphylaxis in dialysis patients as it reduces the activation of <strong>matrix GLA protein</strong>, which normally helps prevent vascular calcification.</li>\r\n<li><strong>Management of calciphylaxis</strong> involves:\r\n<ul>\r\n<li><strong>Discontinuation of warfarin</strong> to halt further progression.</li>\r\n<li>Treatments such as <strong>hyperbaric oxygen therapy</strong> and <strong>IV thiosulfate</strong> to promote healing and reduce vascular calcification.</li>\r\n<li>Use of <strong>calcimimetic agents</strong> like <strong>cinacalcet</strong> can enhance sensitivity of parathyroid cells to calcium, helping regulate phosphate and calcium levels, which may prevent calciphylaxis.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A. Vasculitis:</strong> Presents with systemic symptoms and organ involvement, not just localized nodules and skin changes.</li>\r\n<li><strong>B. Cardioembolism causing obstruction of cutaneous vessels resulting in skin infarct:</strong> While it could cause skin infarction, it would not typically present with livedo reticularis or nodules.</li>\r\n<li><strong>C. Necrotizing infection:</strong> Usually accompanied by systemic signs of infection (fever, increased WBC), which are not noted in this case.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Calciphylaxis</strong> is a <strong>devastating complication</strong> of advanced CKD, presenting with <strong>painful nodules</strong> and <strong>skin necrosis</strong>, particularly in patients on <strong>warfarin</strong>.</li>\r\n<li>Effective management includes <strong>discontinuation of warfarin</strong>, use of <strong>hyperbaric oxygen</strong>, <strong>IV thiosulfate</strong>, and consideration of <strong>cinacalcet</strong> to manage calcium and phosphate levels.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperphosphatemia</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased FGF23</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperparathyroidism</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following CKD related biochemical changes are considered risk factor for vascular disease (e.g Hypertension)?</span></p>",
      "unique_key": "DT1295638",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295638,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Vascular disease prevalence in CKD is influenced by both traditional (hypertension, diabetes) and nontraditional risk factors (CKD-related).</strong></li>\r\n<li>Traditional risk factors include:\r\n<ul>\r\n<li>Hypertension</li>\r\n<li>Diabetes mellitus</li>\r\n<li>Hypervolemia</li>\r\n<li>Dyslipidemia</li>\r\n<li>Sympathetic overactivity</li>\r\n<li>Hyperhomocysteinemia</li>\r\n</ul>\r\n</li>\r\n<li>Nontraditional risk factors associated with CKD comprise:\r\n<ul>\r\n<li>Anemia</li>\r\n<li>Hyperphosphatemia</li>\r\n<li>Hyperparathyroidism</li>\r\n<li>Increased FGF-23</li>\r\n<li>Sleep apnea</li>\r\n<li>Systemic inflammation</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Management-essential facts to remember:</strong></p>\r\n<ul>\r\n<li>Target BP&lt;130/80 mmHg</li>\r\n<li><strong>ACE/ARB may initially increase serum creatinine</strong>. If the rise of serum creatinine is <strong>less than 30% of baseline</strong>, they can be continued with regular monitoring of serum potassium and creatinine.</li>\r\n<li>The use of the gliflozins (SGLT2 inhibitors) in patients with diabetes mellitus has recently been associated with kidney protection and a reduction in cardiovascular events, including heart failure. Currently under study is the feasibility of using gliflozins in nondiabetic CKD.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li>A: <strong>Hyperphosphatemia</strong> is a known risk factor for vascular disease.</li>\r\n<li>B: Increased <strong>FGF23</strong> is associated with increased cardiovascular risk in CKD.</li>\r\n<li>C: <strong>Hyperparathyroidism</strong> contributes to vascular calcification and cardiovascular complications<strong>.</strong></li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>All three biochemical changes-hyperphosphatemia, increased FGF23, and hyperparathyroidism-are risk factors for vascular disease in CKD.</li>\r\n<li>Management of hypertension in CKD should aim for a target BP &lt; 130/80 mmHg, and monitoring of traditional and CKD-specific risk factors is crucial to reduce cardiovascular.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Microcytic hypochromic anaemia</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Normocytic Normochromic Anaemia</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Microcytic Normochromic Anemia</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Most common of anaemia seen in Patients of chronic Kidney disease is?</span></p>",
      "unique_key": "DT1295640",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295640,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Normocytic, normochromic anemia</strong> is prevalent as early as <strong>stage 3 CKD</strong> and becomes nearly universal by <strong>stage 4</strong>.</li>\r\n<li>The <strong>primary cause</strong> is the <strong>insufficient production</strong> of <strong>erythropoietin (EPO)</strong> by damaged kidneys.</li>\r\n<li><strong>Additional causes</strong> of anemia in CKD include:\r\n<ul>\r\n<li>Relative deficiency of EPO</li>\r\n<li>Diminished red blood cell survival</li>\r\n<li>Bleeding diathesis</li>\r\n<li>Iron deficiency from poor dietary absorption and gastrointestinal blood loss</li>\r\n<li>Hyperparathyroidism and bone marrow fibrosis</li>\r\n<li>Chronic inflammation</li>\r\n<li>Nutritional deficiencies (Folate, Vitamin B12)</li>\r\n<li>Hemoglobinopathy</li>\r\n<li>Comorbid conditions (e.g., hypo-/hyperthyroidism, pregnancy, HIV, autoimmune diseases)</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong> Microcytic hypochromic anemia</strong>: More commonly associated with iron deficiency, which is not the primary cause in CKD.</li>\r\n<li><strong> Microcytic normochromic anemia</strong>: Not typical in CKD; usually associated with iron deficiency.</li>\r\n<li><strong> None of the above</strong>: Incorrect as normocytic normochromic anemia is the correct answer.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Normocytic normochromic anemia</strong> is the most common anemia in CKD, primarily due to <strong>insufficient EPO production</strong>.</li>\r\n<li>Management includes targeting hemoglobin levels of <strong>100&ndash;115 g/L</strong> and considering <strong>new therapies</strong> like <strong>prolyl-hydroxylase inhibitors</strong> to enhance EPO production.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic nephropathy</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic interstitial nephritis</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Amyloidosis</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV nephropathy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Chronic kidney disease with normal kidney size is seen in all of the following except?</span></p>",
      "unique_key": "DT1295642",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295642,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Normal kidney size</strong> in the context of chronic kidney disease (CKD) can indicate <strong>acute or subacute conditions</strong> rather than long-standing damage.</li>\r\n<li><strong>Chronic interstitial nephritis</strong> is characterized by progressive scarring of the renal interstitium, typically resulting in <strong>reduced kidney size</strong> over time due to fibrosis.</li>\r\n<li><strong>Exceptions</strong> where kidney size may remain normal despite CKD include:\r\n<ul>\r\n<li><strong>Diabetic nephropathy</strong>: Initially, kidneys can be enlarged due to <strong>hyperfiltration</strong> and increased glomerular volume, but they may become small in later stages of the disease.</li>\r\n<li><strong>Amyloidosis</strong>: The kidneys can maintain a normal size even as function deteriorates due to amyloid deposition affecting glomerular function without causing significant enlargement or reduction.</li>\r\n<li><strong>HIV nephropathy</strong>: This condition may also present with normal kidney size in CKD due to direct viral effects on renal parenchyma and associated immune responses without significant hypertrophy or atrophy.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Diabetic nephropathy</strong>: Initially presents with enlarged kidneys before progressing to CKD.</li>\r\n<li><strong>C. Amyloidosis</strong>: May also have normal kidney size in the context of CKD.</li>\r\n<li><strong>D. HIV nephropathy</strong>: Can maintain normal kidney size while having CKD.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Chronic kidney disease</strong> with <strong>normal kidney size</strong> is often observed in <strong>diabetic nephropathy, amyloidosis, and HIV nephropathy</strong>, but not in <strong>chronic interstitial nephritis</strong>.</li>\r\n<li>Normal kidney size may indicate a more <strong>acute process</strong> or specific conditions, while <strong>shrunken kidneys</strong> suggest long-standing CKD.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">B blockers</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Gliflozins</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and C</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following class of drugs has proven role in reducing intraglomerular hypertension and proteinuria and hence reduces progression of diabetic kidney disease?</span></p>",
      "unique_key": "DT1295644",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295644,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>ACE inhibitors</strong> (Angiotensin-Converting Enzyme inhibitors) and <strong>ARBs</strong> (Angiotensin Receptor Blockers) are well-established in reducing <strong>intraglomerular hypertension</strong> and <strong>proteinuria</strong> in both diabetic and non-diabetic chronic kidney disease (CKD).</li>\r\n<li><strong>Gliflozins</strong> (SGLT2 inhibitors) specifically show efficacy in reducing <strong>intraglomerular pressure</strong> and <strong>proteinuria</strong> in patients with diabetic kidney disease. Ongoing trials are evaluating their effects in non-diabetic CKD.</li>\r\n<li>The <strong>combined use</strong> of ACE inhibitors or ARBs with gliflozins can provide <strong>synergistic benefits</strong> in managing diabetic kidney disease progression.</li>\r\n<li><strong>Calcium channel blockers</strong>, particularly <strong>diltiazem</strong> and <strong>verapamil</strong>, may also offer <strong>antiproteinuric and renoprotective effects</strong> compared to dihydropyridine calcium channel blockers, although their primary role is not to reduce intraglomerular hypertension like ACE inhibitors and gliflozins.</li>\r\n<li>The development of <strong>genome-specific therapies</strong> for conditions such as <strong>ADPKD</strong> (Autosomal Dominant Polycystic Kidney Disease) and APOL1-mediated kidney disease is underway, indicating a future direction in targeted treatments for kidney diseases.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. ACE inhibitors</strong>: Although effective, they are not the only class of drugs involved; hence not alone the correct answer.</li>\r\n<li><strong>B. B blockers</strong>: They primarily manage heart rate and blood pressure but lack direct renoprotective roles in CKD.</li>\r\n<li><strong>C. Gliflozins</strong>: While effective in diabetic CKD, they do not address non-diabetic CKD, making them incomplete as a standalone answer.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>ACE inhibitors and gliflozins</strong> both play a crucial role in <strong>reducing intraglomerular hypertension and proteinuria</strong>, essential for slowing progression of <strong>diabetic kidney disease</strong>.</li>\r\n<li>The combined use of these medications can optimize treatment and provide significant <strong>renoprotective effects</strong> in diabetic patients, highlighting the importance of multifaceted management in CKD.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">To prevent hypertension</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">To prevent hyponatremia</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">To prevent hypotension</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">To prevent Hypernatremia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Sodium Modelling during dialysis is used for management of which of the following complication?</span></p>",
      "unique_key": "DT1295646",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295646,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Sodium Modelling</strong> helps <strong>prevent hypotension</strong> during dialysis by adjusting the <strong>dialysate sodium concentration</strong> from higher levels (145-155 mmol/L) to isotonic levels (136-140 mmol/L) towards the end of treatment, countering osmolar gradients.</li>\r\n<li>The <strong>usual dialysate calcium concentration</strong> is <strong>25 mmol/L</strong>, adjustable for specific needs (e.g., hypocalcemia).</li>\r\n<li><strong>Diffusive clearance</strong> is the primary mechanism for removing metabolic toxins during hemodialysis.</li>\r\n<li>The mechanism of clearance of metabolic toxins during hemodialysis is <strong>diffusive clearance&gt;&gt;Ultrafiltration.</strong></li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. To prevent hypertension</strong>: Sodium modelling targets hypotension, not hypertension.</li>\r\n<li><strong>B. To prevent hyponatremia</strong>: It does not primarily focus on preventing hyponatremia.</li>\r\n<li><strong>D. To prevent hypernatremia</strong>: The goal is managing hypotension, not hypernatremia.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Sodium Modelling</strong> is crucial for <strong>preventing hypotension</strong> during dialysis by optimizing sodium concentrations.</li>\r\n<li>This technique enhances <strong>patient stability</strong> in CKD treatment, demonstrating the importance of tailored dialysis protocols.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">% decrease in Serum creatinine</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Urea reduction ratio</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Body water-indexed clearance &times; time product (Kt/V)</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Both B and C</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is used to measure of adequacy of dialysis?</span></p>",
      "unique_key": "DT1295649",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295649,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Urea Reduction Ratio (URR)</strong> and <strong>Kt/V</strong> are critical metrics for assessing <strong>dialysis adequacy</strong>:\r\n<ul>\r\n<li><strong>URR</strong> measures the <strong>fractional reduction</strong> in blood urea nitrogen during hemodialysis sessions, with targets of <strong>&gt;65-70%</strong>.</li>\r\n<li><strong>Kt/V</strong> measures <strong>dialyzer clearance</strong> over time, with target values of <strong>&gt;1.2</strong> or <strong>05</strong> based on urea concentration equilibrations.</li>\r\n</ul>\r\n</li>\r\n<li>Most patients with <strong>End-Stage Kidney Disease (ESKD)</strong> require <strong>9-12 hours of dialysis weekly</strong>, typically split into three sessions.</li>\r\n</ul>\r\n<p><strong>Complications During Dialysis:</strong></p>\r\n<ul>\r\n<li><strong>Hypotension</strong>: Most common acute complication, especially in diabetic patients. Management includes:\r\n<ul>\r\n<li>Discontinuing ultrafiltration.</li>\r\n<li>Administering isotonic saline or salt-poor albumin.</li>\r\n<li>Preventive measures: Careful dry weight evaluation, ultrafiltration modeling, and avoiding heavy meals.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Dialyzer Reactions</strong>:\r\n<ul>\r\n<li><strong>Type A</strong>: IgE-mediated hypersensitivity to ethylene oxide, can cause anaphylaxis; requires prompt treatment.</li>\r\n<li><strong>Type B</strong>: Nonspecific symptoms (chest/back pain) from complement activation; symptoms typically resolve with continued dialysis.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. % decrease in Serum creatinine</strong>: This is not a reliable measure for dialysis adequacy.</li>\r\n<li><strong>B. Urea reduction ratio</strong>: Although important, it is incomplete without Kt/V.</li>\r\n<li><strong>C. Kt/V</strong>: While essential, it must be combined with the urea reduction ratio for comprehensive assessment.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Both Urea Reduction Ratio and Kt/V</strong> are essential for determining the <strong>adequacy of dialysis</strong>.</li>\r\n<li>Meeting target values is crucial for effective <strong>management of ESKD</strong>, ensuring optimal patient outcomes during treatment.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">E. coli</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Pseudomonas</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Staphylococcus</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Klebsiella</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is most common organism causing peritonitis in patients undergoing peritoneal dialysis?</span></p>",
      "unique_key": "DT1295652",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295652,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Peritonitis</strong> is a significant complication of <strong>peritoneal dialysis</strong>, often indicated by:\r\n<ul>\r\n<li><strong>Elevated peritoneal fluid leukocyte count</strong>: &gt;100/mm&sup3; with at least <strong>50% polymorphonuclear neutrophils</strong>.</li>\r\n</ul>\r\n</li>\r\n<li>The most common organisms responsible for peritonitis are <strong>gram-positive cocci</strong>, particularly <strong>Staphylococcus</strong>, due to their skin origin.</li>\r\n<li><strong>Gram-negative rod infections</strong> are less frequent, and other infections (fungal, mycobacterial) can occur, especially after antibacterial treatments.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. E. coli</strong>: While it is a common organism, it is not the most prevalent cause of peritonitis in this context.</li>\r\n<li><strong>B. Pseudomonas</strong>: Less commonly associated with peritonitis; primarily found in catheter-related infections.</li>\r\n<li><strong>D. Klebsiella</strong>: Not a primary cause; it is less frequently isolated in peritonitis cases compared to Staphylococcus.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Staphylococcus</strong> is the most common organism causing peritonitis in patients on <strong>peritoneal dialysis</strong>.</li>\r\n<li>Awareness of infection types is crucial for early diagnosis and management of <strong>peritonitis</strong>, improving patient outcomes in dialysis settings.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Herpes virus</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Cytomegalovirus</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspergillus</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following organisms commonly causes peri transplant (<1 month) infection in renal transplant patients?</span></p>",
      "unique_key": "DT1295654",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295654,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Herpes virus</strong> is a common cause of infection in renal transplant patients within the first month post-transplant, often due to reactivation of latent infections or transmission from the donor.\r\n<ul>\r\n<li><strong>Must-Know Fact</strong>: Early intervention is essential as these infections can lead to significant morbidity in transplant patients.</li>\r\n</ul>\r\n</li>\r\n<li>While <strong>Cytomegalovirus (CMV)</strong> is significant, it usually presents after the first month. It is more prevalent in seronegative recipients of seropositive donors, typically appearing later with more systemic symptoms.\r\n<ul>\r\n<li><strong>Must-Know Fact</strong>: CMV can range from asymptomatic viremia to systemic syndromes, with plasma viral load and rise in IgM antibodies being diagnostic.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Aspergillus</strong> is more associated with late infections due to its opportunistic nature, often appearing after the initial recovery phase.\r\n<ul>\r\n<li><strong>Must-Know Fact</strong>: Opportunistic infections like Aspergillus typically occur later in the transplant course, necessitating close monitoring.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109786f40ff-cd19-4f5f-ab06-02fda3385c7d.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B. Cytomegalovirus</strong>: Primarily causes infections beyond the immediate post-transplant period; not typically a &lt;1 month infection.</li>\r\n<li><strong>C. Aspergillus</strong>: Generally associated with later infections, particularly in immunocompromised patients.</li>\r\n<li><strong>D. All of the above</strong>: Incorrect, as only herpes virus is the primary cause of early peri-transplant infections.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Herpes virus</strong> is the primary organism causing peri-transplant infections within the first month in renal transplant patients.</li>\r\n<li><strong>Vigilance</strong> for early infections is crucial in transplant patients, emphasizing the need for effective monitoring and management strategies.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclosporine</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Sirolimus</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Tacrolimus</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a mTOR inhibitor used for maintenance therapy in Renal transplant patient?</span></p>",
      "unique_key": "DT1295656",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295656,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Sirolimus</strong> is a specific mTOR (mechanistic target of rapamycin) inhibitor used in maintenance therapy for renal transplant patients. It inhibits cell proliferation and reduces the risk of acute rejection.</li>\r\n<li><strong>Cyclosporine</strong> and <strong>Tacrolimus</strong> are both calcineurin inhibitors, not mTOR inhibitors. They are commonly used for immunosuppression but do not belong to the mTOR inhibitor class.</li>\r\n</ul>\r\n<p><strong>About Immunosuppressive Drugs in Renal Transplant Patients:</strong></p>\r\n<ul>\r\n<li><strong>mTOR Inhibitors</strong>:\r\n<ul>\r\n<li><strong>Sirolimus</strong> and <strong>Everolimus</strong> are key agents that help in minimizing the risk of acute rejection while managing nephrotoxicity.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Calcineurin Inhibitors</strong>:\r\n<ul>\r\n<li><strong>Cyclosporine</strong> and <strong>Tacrolimus</strong> are effective for immunosuppression but have associated renal toxicity and require close monitoring.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Steroids</strong>:\r\n<ul>\r\n<li>Often used in combination with other immunosuppressants for their anti-inflammatory effects during the early post-transplant period.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Antibody Therapies</strong>:\r\n<ul>\r\n<li><strong>Basiliximab</strong> and <strong>Alemtuzumab</strong> can be used for induction therapy to prevent acute rejection in high-risk patients.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Cyclosporine</strong>: Incorrect, as it is a calcineurin inhibitor, not an mTOR inhibitor.</li>\r\n<li><strong>C. Tacrolimus</strong>: Also incorrect; it is a calcineurin inhibitor with similar effects to cyclosporine.</li>\r\n<li><strong>D. All of the above</strong>: Incorrect because only Sirolimus is an mTOR inhibitor.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Sirolimus</strong> is the only mTOR inhibitor listed and is essential for maintenance therapy in renal transplant patients.</li>\r\n<li>Understanding the <strong>classes of immunosuppressants</strong> is crucial for effective management and minimizing adverse effects post-transplant.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}